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Available online 22 April 2016Background: Type 2 diabetes (T2D) is associated with an increased risk of ischaemic heart disease (IHD). An ac-
celerated process of vascular ageing induced by an increased oxidative stress exposure is suggested as potential
pathway accounting for this association. However, no studies have explored the relationship betweenmarkers of
vascular ageing, measures of oxidative stress and risk of IHD in T2D.
Objectives: To explore the association between plasma antioxidant status, marker of cellular ageing (leukocyte
telomere length, LTL) and 10 years risk of IHD in patients with T2D.
Methods: Between 2001 and 2002, 489 Caucasians subjects with T2Dwere enrolled at the diabetic clinic, Univer-
sity College London Hospital. Plasma total anti-oxidant status (TAOS) and LTL were measured by photometric
microassay and RT-PCR, respectively. The incidence of IHD over 10 years was determined through linkage with
the national clinical audit of acute coronary syndrome in UK.
Results: At baseline, TAOS was associated with LTL (age adjusted: r = 0.106, p = 0.024). After 10 years, 61 pa-
tients developed IHD. Lower TAOS and shorter LTL at baseline predicted an increased IHD risk at follow-up
(age adjusted: p= 0.033 and p= 0.040, respectively). These associations were independent of age, gender, car-
diovascular risk factors, circulating levels of CRP and medication differences.
Conclusions: Reduced TAOS and short LTL are interrelated pathways which predict risk of IHD in patients with
T2D. Our ﬁndings suggest that antioxidant defences are important tomaintain telomere integrity, potentially re-
ducing the progression of vascular ageing in patients with T2D.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Telomeres1. Introduction
Type 2 diabetes mellitus (T2D) is a chronic disease characterized by
multiple metabolic derangements, which disrupt the balance between
reactive oxygen species and antioxidant defences at the cellular level
[1]. Antioxidant capacity of plasma is the primary measure and marker
to evaluate the status and potential of oxidative stress in the body. Plas-
ma contains many compounds, which function against the oxidative
stressors in the body thus protecting the cell and cellular biomolecules
from being damaged. The reduced antioxidant capacity described inar Science, University College
C1A 4NP London, UK.
land Ltd. This is an open access articlpatients with diabetes results in greater exposure to oxidative stress
and subsequent damage to proteins, lipids, and DNA, which leads to a
rapid deterioration of a broad range of cellular functions and premature
cellular ageing [2,3]. These mechanisms underpin the development of
several diabetic complications, including ischaemic heart disease
(IHD) [4]. T2D can therefore be regarded as a model of accelerated
biological ageing due to increased levels of oxidative stress exposure,
and the increased risk of IHD as a manifestation of premature vascular
ageing [5].
Over the last ten years, epidemiological studies have suggested that
peripheral blood leukocyte telomere length (LTL) can be a useful bio-
marker of cardiovascular ageing. Multiple reports [6–9], including a re-
centmeta-analysis andGWAS study [10,11], suggested that LTL is on the
causal pathways for IHD. The association between LTL and IHD is
thought to be mediated by oxidative stress exposure which is currentlye under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cations [12] as well as to cause a faster LTL attrition [13]. However, the
impact of a reduced antioxidant capacity on LTL and risk of IHD has
not been explored in patients with T2D.
We have studied a well characterised cohort of patients with T2D in
order to explore the relationship between a baseline measure of total
serum antioxidant capacity and LTL with subsequent risk of IHD over
10 years.
2. Methods
2.1. Study sample
The University College Diabetes and Cardiovascular disease (UDAC)
study comprises 1011 individuals, who were recruited consecutively
from the diabetes clinic at UCL Hospitals in 2001–2. The study was de-
signed to investigate the association between inﬂammatory/metabolic
genes and biochemical risk factors implicated in IHD in patients with di-
abetes. The study has been described in detail elsewhere [14,15]. All pa-
tients had type 1 or type 2 diabetes according to WHO criteria [16].
Anthropometric measures (height, weight and BMI), blood pressure
and blood samples as well as information on smoking history and cur-
rent medication use were collected during their routine diabetes clinic
appointment. Our analysis focuses on the subgroup of individuals of in-
dividuals with a diagnosis of T2D, of Caucasian origin andwith available
measures of plasma total anti-oxidant status (TAOS), LTL and cardiovas-
cular outcome (n= 489, Fig. 1S of Supplementary Material). The ratio-
nale for the restriction of the analysis to the T2D and Caucasian groups
was to reduce the heterogeneity of our study sample, due to the
known differences in the pathogenesis of cardiovascular complication
between different types of diabetes [17] and the different LTL distribu-
tions and rates of attrition amongst ethnic groups [18,19]. Further, de-
spite multiple studies documented that LTL can predict the risk of IHD
in White American and Caucasian populations, there are no reports as
of yet on South Asian populations with or without diabetes. Ethical ap-
proval was granted by UCL/UCLH Ethics Committee and all subjects
gave written informed consent.
2.2. Plasma total anti-oxidant status and cardiovascular risk factor assays
Plasma samples were collected within the 12-month recruitment
period and stored immediately at−80 °C. Plasma total anti-oxidant sta-
tus (TAOS) wasmeasured by Sampson's modiﬁcation of Laight's photo-
metric microassay [20], using 2.5 μL citrated plasma samples in 96-well
ELISA plates. TAOS was selected as: a) it correlates with markers of ox-
idative damage in peripheral blood of patient with diabetes [20,21];
b) there is already evidence supporting a different anti-oxidant status
of patients with type 1 or type 2 diabetes when compared to healthy
controls [22,23]; c) it is associated with subclinical atherosclerosis coro-
nary artery disease events in observational and longitudinal studies in-
cluding patients with and without diabetes [21,24]. Inter- and intra-
assay coefﬁcients of variation were 14.1% and 4.3%, respectively. Levels
of total cholesterol, triglycerides, HDL cholesterol and HbA1c were
assayed according to standard chemistry protocols [25]. LDL cholesterol
was calculated by the Friedwald equation.
2.3. DNA extraction and LTL assay
Leukocyte DNA was extracted by the salting-out method [26]. Telo-
mere length was measured using a validated quantitative PCR-based
method as previously described [27]. Brieﬂy, the relative telomere
length was calculated as the ratio of telomere repeats to single-copy
gene (SCG) copies (T/S ratio). For each sample the quantity of telomere
repeats and the quantity of SCG copies were determined in comparison
to a reference sample in a telomere and a SCG quantitative PCR, respec-
tively. The raw data from each PCR was analysed using the comparativequantiﬁcation analysis (Rotor-Gene 6000 software, Corbett Research
Ltd., Cambridge, UK). All PCRs were performed on the Rotor-Gene
6000 (Corbett Research Ltd., Cambridge, UK). The coefﬁcient of varia-
tion in repeated measurements was 5.6%.
2.4. Coronary heart disease data
Data on incident IHD disease was retrieved from the Myocardial Is-
chaemia National Audit Project (MINAP), heldwithin theNational Insti-
tute of Cardiovascular Outcome and Research (NICOR). This is a national
registry of patients admitted to hospitals in England and Wales with
acute coronary syndromes (ACS). It was established in 1998 to provide
participating hospitals with a common mechanism for auditing perfor-
mance against standards deﬁned in the National Service Framework
for Coronary Heart Disease [28]. Data collection began in October 2000
and by mid-2002 all acute hospitals in England and Wales were partic-
ipating in the registry. The characteristics, organization, availability,
data quality, validation and accessibility of cardiovascular outcome
data contained in the MINAP have been previously described [29]. A
new diagnosis of IHD diseasewas identiﬁed using hospital discharge re-
cords, markers of myocardial necrosis, results of coronary angiograms
and coded electrocardiographic ﬁndings, in accordance with the inter-
nationally agreed deﬁnition of ST-segment elevation myocardial infarc-
tion (STEMI) [30] and acute coronary syndrome without persistent ST-
segment elevation [30–32].
2.5. Statistical analysis
Mean values between groups were compared using two sample t-
tests. Normality was tested using the Shapiro–Wilk test. Variables were
log-transformed where necessary to normalise the distribution and geo-
metric means and approximated standard deviations are reported for
these variables with t-tests performed on the log-transformed data.
Where the data could not be normalised, medians and interquartile
ranges are presented and differences were tested using the Mann–Whit-
ney U test. For categorical variables, chi-squared tests were used. Associ-
ation between continuous variables was assessed by Spearman rank
correlation. Adjustment was made for covariates by including them as
terms in regression or logistic regression models. Particularly, a series of
multivariable regression models were ﬁtted to examine whether tradi-
tional CV risk factors and other potential confounders inﬂuenced the as-
sociation observed between LTL and the risk of IHD disease. Results
from three multiple regression models are reported: model 1 = age
adjusted; model 2 = model 1 + adjustments for sex, HbA1c and
smoking; model 3 = model 2 + adjustments for total cholesterol,
blood pressure, C-reactive protein (CRP) and medications. Additionally,
we explored whether further adjustment of model 2 for speciﬁc classes
of anti-hypertensive medications (angiotensin converting enzyme, an-
giotensin receptor blockers or calcium channel blockers) had an impact
on the association of TAOS or LTL with IHD. Theα value for statistical sig-
niﬁcance for associations was set at 0.05. Analyses were performed with
STATA version 13.
3. Results
3.1. Baseline characteristics
At baseline, the patients studied were overweight, exhibited subop-
timal gluco-metabolic control, and relatively high levels of blood pres-
sure (Table 1). The average TAOS was 44.8% [36.5–53.3] and it was
higher in people with longer LTL (unadjusted: r = 0.093, p = 0.046;
age adjusted: r = 0.106, p = 0.024) and higher levels of HDL-
cholesterol, while it was reduced in patients with elevated glucose,
HbA1c and triglycerides levels (Table 1). Furthermore, LTLwas inversely
associated with age (r =−0.150; p = 0.002), while there were no dif-
ferences based on gender or cigarette smoking distribution, nor was LTL
Table 1
Baseline characteristics of the study sample and their associations with TAOS and LTL.
Characteristics N = 489 Association with
TAOS
Association with
LTL
r p r p
Age, yearse 67 [24–91] 0.078 0.089 −0.150 0.002
Smoking, %c 77 (16%) −0.0007 0.987 −0.019 0.685
BMI, Kg/m2b 29.4 ± 5.6 −0.058 0.204 −0.0025 0.957
SBPf, mm Hgb 141 ± 19 0.075 0.104 0.061 0.192
DBPf, mm Hgb 79 ± 11 0.067 0.145 −0.034 0.473
Total cholesterol,
mmol/La
5.15 ± 1.06 −0.035 0.450 0.040 0.396
LDL, mmol/La 2.79 ± 0.92 0.023 0.625 0.068 0.149
HDL, mmol/Lb 1.29 ± 0.37 0.132 0.004 −0.003 0.942
Triglyceride, mmol/Lb 1.93 ± 1.09 −0.178 0.0001 −0.055 0.239
CRP, mg/Lb 1.76 ± 1.51 0.074 0.106 −0.092 0.051
Glucose, mmol/Lb 10.00 ± 4.31 −0.164 0.0003 −0.054 0.251
Hba1c, % (mmol/mol)b 7.66 ± 1.64 −0.100 0.030 0.011 0.817
TAOS, %d 44.8 [36.5–53.3] – – 0.106 0.024
Age adjusted LTL, T/S
ratiob
0.97 ± 0.21 0.106 0.024 – –
Statin treatment, %c 124 (26%) −0.010 0.833 0.022 0.646
BP lowering, %c 316 (65%) −0.0007 0.987 −0.013 0.785
Apart from the association with age, all other associations with LTL were adjusted for age.
The α value for statistical signiﬁcance for associations was set at 0.05.
a Mean ± standard deviation for normally distributed variables.
b Geometric mean ± approximate standard deviation for log-normally distributed
variables.
c N (percentage) for binary variables.
d Median [interquartile range] for not normally distributed variables.
e Age is show as median [range].
f SBP: systolic blood pressure; DBP: diastolic blood pressure.
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total cholesterol, HDL-cholesterol, systolic and diastolic blood pressure
and HbA1c. Subjects with shorter LTL tended to have elevated levels of
circulating CRP (Table 1).Table 2
Baseline differences between ischaemic and non-ischaemic groups.
Characteristics Non-ischaemic
N = 428
Ischaemic
N = 61
p value
Age, yearse 66 [24–91] 67 [44–84] 0.725
Smoking, %c 70 (17%) 7 (12%) 0.344
BMI, Kg/m2b 29·1 ± 5.6 30.9 ± 5.8 0.026
SBPf, mm Hgb 142 ± 18 140 ± 23 0.444
DBPf, mm Hgb 79 ± 11 76 ± 10 0.037
Total cholesterol, mmol/La 5.18 ± 1.08 4.94 ± 0.97 0.094
LDL, mmol/La 2.80 ± 0.93 2.69 ± 0.90 0.353
HDL, mmol/Lb 1.30 ± 0.38 1.17 ± 0.29 0.004
Triglyceride, mmol/Lb 1.90 ± 1.08 2.17 ± 1.08 0.087
CRP, mg/Lb 1.70 ± 1.46 2.17 ± 1.90 0.041
Glucose, mmol/Lb 9.94 ± 4.33 10.38 ± 4.15 0.471
Hba1c, % (mmol/mol)b 7.67 (60) ± 1.67 7.63 (60) ± 1.43 0.865
TAOS, %d 44.5 [36.9–53.3] 40.5 [32.3–47.8] 0.033
Age adjusted LTL, T/S ratiob 0.98 ± 0.21 0.92 ± 0.18 0.040
Statin treatment, %c 94 (22%) 30 (50%) b0.001
BP lowering, %c 268 (63%) 48 (79%) 0.019
Differences between ischaemic and non-ischaemic groups were assessed using unpaired
t-test for normally or log-normally distributed variables.Where the data could not be nor-
malised,medians and interquartile ranges are presented anddifferenceswere testedusing
the Mann–Whitney U test. χ [2] tests were used for categorical variables.
a Mean ± standard deviation for normally distributed variables.
b Geometric mean ± approximate standard deviation for log-normally distributed
variables.
c N (percentage) for binary variables.
d Median [interquartile range] for not normally distributed variables.
e Age is show as median [range].
f SBP: systolic blood pressure; DBP: diastolic blood pressure.3.2. Cardiovascular outcomes
After 10 years, 61 patients (12.5%) developed IHD disease. Patients
with IHD had higher baseline BMI and CRP but lower levels of HDL-
cholesterol compared to those in the non-ischaemic group (Table 2).
Notably, the IHD disease group had lower baseline TAOS compared to
the non-ischaemic group (unadjusted: p = 0.033; adjusted for age:
p=0.016) (Fig. 1). This associationwas not affected by adjustments in-
cluded in model 2 (p= 0.028) and remained signiﬁcant in the fully ad-
justed model (p = 0.022) (Table 3). Similarly, age-adjusted LTL was
shorter in the IHD disease group compared to the non-ischaemic
group (unadjusted: p = 0.040; adjusted for age: p = 0.039) (Fig. 2).
This difference was not affected by adjustments included in model 2
(p = 0.034) and remained signiﬁcant in the fully adjusted model
(model 3, p = 0.020) (Table 4). Adjustment for medication use
(Model 3 of Table 3 and 4) as well as for different classes of anti-
hypertensives did not materially affect the association between TAOS
and IHD, nor the association between LTL and IHD (Tables 1S and 2S
of Supplementary Material).
4. Discussion
This is the ﬁrst study to explore the association between LTL, antiox-
idant capacity and subsequent risk of IHD disease in patients with T2D.
We showed that baseline LTL was inversely related to TAOS and that
shorter LTL and lower TAOS at baseline predicted IHD disease risk
over 10 years, independently from traditional cardiovascular risk fac-
tors. This suggests that a reduced antioxidant capacity increases the
risk of IHD in patients with T2D, potentially accelerating the vascular
ageing process by damaging telomere sequences.
Previous reports have described associations between LTL and inci-
dence of IHD in healthy populations [6–8]. In T2D, only observational
studies have reported associations between LTL and prevalence of dia-
betes complications [33].We now show that LTL can predict future inci-
dence of IHD disease in prospective follow-up over 10 years. This is
likely to be due to the unique ability of LTL to reﬂect an individual's cu-
mulative exposure to inﬂammation and oxidative stress. Indeed, it is
nowwell established that oxidative stress exposure increases LTL short-
ening and contributes to the initiation and progression of atherosclero-
sis. A higher oxidative stress exposure results in LDL oxidation, vascular
inﬂammation and increased vulnerability of atherosclerotic plaques to
rupture [12]. Similarly, oxidative stress exerts amajor inﬂuence on telo-
mere dynamics for two principal mechanisms. Firstly, the GGG triplets
on the telomere sequence are highly sensitive to the hydroxyl radical
[13]. Thus, conditions characterised by increased levels of oxidativeFig. 1. Box plot showing difference of TAOS at baseline between ischaemic and non-
ischaemic groups (median and IQR); p = 0.033.
Table 3
Multivariable models assessing differences of TAOS between non-ischaemic and ischae-
mic heart disease groups.
Models Variables Logistic regression
ORa (95% CI) p values
Model 1 Age (1 year increase) 1.01 (0.98–1.03) 0.537
TAOS (1 quintile increase) 0.78 (0.64–0.95) 0.016
Model 2 Age (1 year increase) 1.01 (0.98–1.03) 0.555
Sex (female: male) 0.61 (0.34–1.11) 0.104
Hba1c (1 SD increase) 1.04 (0.78–1.38) 0.788
smoking (current vs. non) 0.67 (0.29–1.57) 0.361
TAOS (1 quintile increase) 0.80 (0.65–0.98) 0.028
Model 3 Age (1 year increase) 1.00 (0.97–1.03) 0.880
Sex (female: male) 0.45 (0.23–0.86) 0.017
Hba1c (1 SD increase) 0.98 (0.71–1.34) 0.984
Smoking (current vs. non) 0.73 (0.30–1.78) 0.494
SBP (1 SD increase) 1.13 (0.76–1.68) 0.552
DBP (1 SD increase) 0.64 (0.43–0.96) 0.030
Blood pressure medications 1.58 (0.79–3.19) 0.197
Lipid lowering medications 3.29 (1.77–6.11) 0.0002
CRP (1 SD increase) 1.48 (1.09–2.03) 0.013
TAOS (1 quintile increase) 0.78 (0.63–0.96) 0.022
a Odds ratio for a unit increase of the independent variable.
Table 4
Multivariable models assessing differences of LTL between non-ischaemic and ischaemic
heart disease groups.
Models Variables Logistic regression
ORa (95% CI) p values
Model 1 Age (1 year increase) 1.00 (0.98–1.03) 0.816
T/S ratio (1 SD increase) 0.74 (0.55–0.99) 0.039
Model 2 Age (1 year increase) 1.00 (0.98–1.03) 0.819
Sex (female: male) 0.56 (0.31–1.04) 0.067
Hba1c (1 SD increase) 1.02 (0.77–1.35) 0.880
Smoking (current vs. non) 0.59 (0.24–1.45) 0.248
T/S ratio (1 SD increase) 0.72 (0.53–0.97) 0.034
Model 3 Age (1 year increase) 0.99 (0.96–1.03) 0.705
Sex (female: male) 0.42 (0.21–0.83) 0.013
Hba1c (1 SD increase) 1.00 (0.72–1.39) 0.984
smoking (current vs. non) 0.72 (0.28–1.85) 0.497
SBP (1 SD increase) 1.09 (0.72–1.64) 0.681
DBP (1 SD increase) 0.67 (0.43–1.02) 0.062
Blood pressure medications 1.73 (0.82–3.62) 0.148
Lipid lowering medications 3.83 (2.02–7.25) 0.00004
CRP (1 SD increase) 1.29 (0.94–1.78) 0.121
T/S ratio (1 SD increase) 0.69 (0.50–0.94) 0.020
a Odds ratio for a unit increase of the independent variable.
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being lost with each cell replication [13]. This has previously been con-
ﬁrmed by Sampson et al., who documented an association between ox-
idative DNA damage and monocyte telomere length in patients with
T2D [34]. Secondly, in contrast to genomic DNA, telomeric DNA was re-
ported to be deﬁcient in the repair of single-strand breaks [35]. As a re-
sult, telomeres appear to be especially vulnerable to the accumulation of
ROS-induced DNA-strand breaks [36].
We found an increased risk of IHD disease in T2D patients with re-
duced antioxidant capacity. A decreased antioxidant capacity is associ-
ated with an increase in oxidative stress which is thought to be on the
causal pathway for diabetic vascular complications. Our study supports
this hypothesis by demonstrating an inverse relationship of TAOS with
risk of IHDdisease risk. In linewith our ﬁndings, Broedbaek et al. recent-
ly showed that higher urinary markers of nucleic acid oxidation are as-
sociatedwith increasedmortality in newly diagnosed patients with T2D
[37]. Despite this, the majority of clinical trials of antioxidants have
failed to show signiﬁcant improvement in CV outcomes in patients
with diabetes [38,39]. This may be due to the inability of exogenouslyFig. 2. Box plot showing difference of LTL at baseline between ischaemic and non-
ischaemic groups; analysis adjusted for age; p = 0.040.provided compounds (like antioxidant vitamins) to reach intracellular
compartments and prevent oxidative damage to key proteins, lipids
and nucleic acids [40].
The association between TAOS and LTL with incident IHD disease
was independent of traditional cardiovascular risk factors. For example,
while people with lower TAOS had higher HbA1c and triglycerides with
lower HDL-cholesterol, adjustment for these cardiovascular risk factors
did not attenuate the association between TAOS and IHD. Similarly,
higher CRP tended to be associated with shorter LTL, as expected [41–
43], but addition of CRP to our fully adjustedmodel did not affect our re-
sults. This ﬁnding could be partially due to comparable cardiovascular
risk factors burden between groups included in this study. Indeed LDL
cholesterol levels were similar between the ischaemic and control
groups, although use of statin was more prevalent in the former. This
observation suggests that, whilst optimal treatment could normalize
cardiovascular risk factors of people with T2D, this might not restore
the antioxidant defences and counteract their impact on the cellular
aging process. This hypotheticalmechanism could explain the increased
residual risk of cardiovascular events observed in people with T2D de-
spite the improved cardiovascular risk factor burden.
Our study has limitations, which may lead to an underestimation of
the strength of the associations between LTL and TAOS with incident
IHD disease. Firstly, the primary outcome was IHD due to the limited in-
formation available on other atherosclerotic complications of diabetes. It
is nowwell established that peoplewith diabetes experience “silent” IHD
during their lifetime. Secondly, the lack of data on non-cardiac causes of
mortality precluded the opportunity to use an event-free survival ap-
proach in our statistical analysis. This, together with the similar follow-
up length for all participants (range 9.3 to 10.5 years), led us to use logis-
tic regression as preferred analytical models to explore the associations
between TAOS and LTLwith IHD. Thirdly,we could not performmeasures
of intracellular antioxidants. TAOS provides an estimation of total antiox-
idant capacity, which in turn is dependent on the contributions of albu-
min, bilirubin and urate. We cannot exclude therefore that measures of
intracellular oxidative stress or the assessment of additional extracellular
antioxidants could provide better estimation of the inﬂuence of antioxi-
dant capacities on LTL and risk of future cardiovascular events. These fac-
tors do not attenuate, however, the importance of the biological
associations emerging from our data. Larger epidemiological studies
with multiple measures of LTL and oxidative stress will be necessary to
provide a more accurate estimation of the associations between TAOS,
LTL and IHD.
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A single measure of antioxidant capacity and LTL predicted 10 years
IHD risk in patients with diabetes. This association is likely to depend
upon an increased damage of the telomere sequence in people with di-
abetes and suggests that a process of early vascular ageing induced by
oxidative stress contributes to increase cardiovascular morbidity and
mortality in diabetes.
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